LSK BioPharma and LSK Global PS Announce a StrategicAlliance for Global Clinical Trials

LSK BioPharma (LSKB), whichis currently developing two promising cancer drugs, announced that it hasentered into a strategic alliance with the largest CRO in Korea, LSK Global PS.The strategic alliance will initially focus on the clinical development ofapatinib, a drug which has been approved in Gastric Cancer (China) and isshowing promise in a number of different solid tumors.

Although the companiesshare common shareholders and a similar name, the two organizations areindependent. The partnership on the development of apatinib provides excellentopportunities for synergy between the companies as apatinib moves into global,multi-center clinical trials in the second half of this year.

LSKB is a privately-heldbiopharmaceutical company based in Salt Lake City, Utah. The Companyspecializes in the early clinical development of promising therapies for unmetmedical needs in cancer. LSKB is developing two exciting drug candidates; asmall molecule angiogenesis inhibitor with potential to treat a variety ofsolid tumors and a Bruton’s Kinase inhibitor with the potential to treathematologic malignancies. LSKB can be found on the web at www.lskbiopharma.com.

LSK Global PS is a fullservice clinical research organization which meets or exceeds internationalstandards. LSK Global PS provides a full range of services in clinical trialsincluding support of Phase I to Phase III, Phase IV, Investigator InitiatedTrials, Post Marketing Surveillance (PMS), and Observational Studies. TheCompany has conducted over 700 clinical trials and has been audited by numerousglobal CROS and MFDS inspections. LSK Global PS, a leading Asian CRO, continuesto expand in participation of global trials. LSK Global PS can be found on theweb at www.lskglobal.com.

Links/Coverage

SEGYE.com
KoreaPharmaceutical Association News
YAKUP.com
Medipana News
Emedico.co.kr
Medical Tribune